{
    "clinical_study": {
        "@rank": "135999", 
        "arm_group": [
            {
                "arm_group_label": "Zolendronic acid + placebo teriparatide", 
                "arm_group_type": "Experimental", 
                "description": "yearly intravenous infusion of 5mg and daily injection of one dose teriparatide"
            }, 
            {
                "arm_group_label": "teriparatide + placebo zoledronic acid", 
                "arm_group_type": "Experimental", 
                "description": "yearly infusion of placebo zoledronic acid (isotonic sodium chloride)and daily injection of one dose active teriparatide"
            }, 
            {
                "arm_group_label": "pcb zoledronic acid + pcb teriparatide", 
                "arm_group_type": "Placebo Comparator", 
                "description": "yearly infusion of placebo zoledronic acid and daily injection of placebo teriparatide"
            }
        ], 
        "brief_summary": {
            "textblock": "Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are\n      fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o. The aim of the\n      present study is to investigate the effect of treatment of adult OI patients with\n      bisphosphonate (zoledronic acid), parathyroid hormone (PTH) or placebo on bone mass,\n      fracture risk and quality of life.\n\n      The investigators will therefore conduct a double blind, placebo controlled trial, taking\n      genotype and previous antiresorptive therapy into account."
        }, 
        "brief_title": "The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteogenesis Imperfecta", 
        "condition_browse": {
            "mesh_term": "Osteogenesis Imperfecta"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  clinical diagnosis of osteogenesis imperfecta\n\n          -  BMD<-2.0 or\n\n          -  BMD<-1 and significant fracture within 3 years\n\n          -  women postmenopausal or using accepted contraception\n\n        Exclusion Criteria:\n\n          -  creatinine clearance <30mL/min\n\n          -  treatment with glucocorticoids > 5mg daily during the last 3 months\n\n          -  metabolic bone disease or vitamin d deficiency\n\n          -  liver or kidney disease\n\n          -  contradictions to zoledronic acid or teriparatide\n\n          -  increased baseline risk of osteosarcoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679080", 
            "org_study_id": "TreatOI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Zolendronic acid + placebo teriparatide", 
                "description": "antiresorptive", 
                "intervention_name": "Zoledronic acid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "zolendronate", 
                    "Aclasta"
                ]
            }, 
            {
                "arm_group_label": "teriparatide + placebo zoledronic acid", 
                "description": "anabolic", 
                "intervention_name": "Teriparatide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "PTH", 
                    "Forsteo"
                ]
            }, 
            {
                "arm_group_label": [
                    "teriparatide + placebo zoledronic acid", 
                    "pcb zoledronic acid + pcb teriparatide"
                ], 
                "intervention_name": "placebo zoledronic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Zolendronic acid + placebo teriparatide", 
                    "pcb zoledronic acid + pcb teriparatide"
                ], 
                "intervention_name": "placebo teriparatide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zoledronic acid", 
                "Teriparatide", 
                "Diphosphonates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug therapy", 
            "Adult"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "janniehald@gmail.com", 
                    "last_name": "Jannie Hald", 
                    "phone": "0045 7846 7686"
                }, 
                "facility": {
                    "address": {
                        "city": "Aarhus", 
                        "country": "Denmark", 
                        "state": "Aarhus C", 
                        "zip": "8000"
                    }, 
                    "name": "Osteoporosis clinic; department of endocrinology and metabolism"
                }, 
                "investigator": {
                    "last_name": "Jannie Hald", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Jens-Erik.Beck.Jensen@hvh.regionh.dk", 
                    "last_name": "Jens-Erik B Jensen"
                }, 
                "facility": {
                    "address": {
                        "city": "Hvidovre", 
                        "country": "Denmark", 
                        "zip": "2650"
                    }, 
                    "name": "Department of endocrinology"
                }, 
                "investigator": {
                    "last_name": "Jens-Erik B Jensen", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lfolkestad@health.sdu.dk", 
                    "last_name": "Lars Folkestad"
                }, 
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark", 
                        "zip": "6000"
                    }, 
                    "name": "Department of Endocrinology M"
                }, 
                "investigator": {
                    "last_name": "Lars Folkestad", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta", 
        "overall_contact": {
            "email": "bente.langdahl@aarhus.rm.dk", 
            "last_name": "Bente Langdahl", 
            "phone": "0045 7846 7678"
        }, 
        "overall_contact_backup": {
            "email": "janniehald@gmail.com", 
            "last_name": "Jannie Hald", 
            "phone": "0045 7846 7681"
        }, 
        "overall_official": {
            "affiliation": "Aarhus University Hospital", 
            "last_name": "Bente Langdahl, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Dual-energy X-ray absorptiometry scans are performed at the lumbar spine, hip and whole body twice yearly. The value of the lumbar BMD is the primary outcome.", 
            "measure": "Bone Mineral Density (BMD)", 
            "safety_issue": "Yes", 
            "time_frame": "Three years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679080"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Participants are asked to report fractures throughout the study. Medical examination yearly with a focus on possible new fractures. Columnar x-ray before and after the study investigate new fractures.", 
            "measure": "Fracture risk", 
            "safety_issue": "No", 
            "time_frame": "Three years"
        }, 
        "source": "University of Aarhus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}